Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
47 results about "Gastrin-releasing peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Gastrin-releasing peptide, also known as GRP, is a neuropeptide, a regulatory molecule that has been implicated in a number of physiological and pathophysiological processes. Most notably, GRP stimulates the release of gastrin from the G cells of the stomach.
Stabilizing Alkylglycoside Compositions and Methods Thereof
ActiveUS20080268032A1Convenient treatmentReduce aggregationBiocidePeptide/protein ingredientsGastrin-releasing peptidePeptide T
The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
Owner:AEGIS THERAPEUTICS LLC
Method, compositions and classification for tumor diagnostics and treatment
InactiveUS20060160157A1Quick and easy determinationImprove survivalCompound screeningApoptosis detectionAbnormal tissue growthSide effect
The present invention is directed towards classifying tumor biomarkers, particularly membrane receptors, and more particularly the gastrin-releasing peptide (GPR) receptors, identified in patient samples, then linking therapeutic agents (chemical, radiological, or biological) to patient-specific ligands that bind to such receptors, clinicians can produce diagnostic and treatment compositions and implement treatment regimens which, by using the classified and identified biomarkers, and due to their improved accuracy, increase success and decrease undesired side effects from such treatments.
Owner:ZUCKERMAN MATHEW MARK
Gastrin Releasing Peptide Compounds
InactiveUS20080008649A1Improve targetingDecreasing aberrant vascular permeabilityRadioactive preparation carriersGastrin releasing peptideCholic acidTherapeutic Hormone
New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and / or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided. Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer, methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer.
Owner:BRACCO IMAGINIG SPA
Gastrin releasing peptide compounds
InactiveUS7226577B2Peptide/protein ingredientsDigestive systemGastrin-releasing peptideImaging agent
New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N-O-P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and / or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.
Owner:BRACCO IMAGINIG SPA
Gastrin releasing peptide compounds
InactiveUS20060018830A1Minimizing interference signalHigh quantum yieldBiocideCarbamic acid derivatives preparationGastrin-releasing peptideImaging agent
New and improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N-O-P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and / or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.
Owner:BRACCO IMAGINIG SPA
Stabilizing alkylglycoside compositions and methods thereof
ActiveUS8226949B2Convenient treatmentReduce aggregationBiocideAntipyreticPeptide TGastrin-releasing peptide
The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
Owner:AEGIS THERAPEUTICS LLC
Gastrin releasing peptide compounds
InactiveUS7611692B2Ultrasonic/sonic/infrasonic diagnosticsPeptide/protein ingredientsGastrin-releasing peptideImaging agent
New and improved compounds for use in diagnostic imaging or therapy having the formula M—N—O—P—G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and / or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.
Owner:BRACCO IMAGINIG SPA
Chemical luminescence immune assay determination reagent kit for gastrin releasing peptide precursor
InactiveCN101368966AImprove linear rangeHas a set of practicabilityChemiluminescene/bioluminescenceGastrin-releasing peptideBiotin
The invention relates to the immunoassay medical field, in particularly provides a chemiluminescence immunoassay test kit and a preparing method thereof for pro gastrin releasing peptide (31-98). Through adopting Biotin-Streptoavidin system coated antibody, the invention can improve antibody coating efficiency, and can improve the sensitivity at the same time. The test kit provides diagnosis of small-cell lung cancer with accurate chemiluminescence test kit which has simple operation and sensitive result detecting, so as to meet the requirements in clinical diagnosis.
Owner:CHEMCLIN DIAGNOSTICS CO LTD
Gastrin releasing peptide compounds
InactiveUS7850947B2Improve targetingIn-vivo radioactive preparationsPeptide/protein ingredientsGastrin-releasing peptideImaging agent
New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure:wherein R1-R5 and FG are define herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and / or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.
Owner:BRACCO IMAGINIG SPA
Gastrin releasing peptide compounds
InactiveUS20040253225A1Low affinityWithout decreasing binding affinityUltrasonic/sonic/infrasonic diagnosticsPeptide/protein ingredientsGastrin-releasing peptideImaging agent
New and improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and / or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.
Owner:BRACCO IMAGINIG SPA
Method, compositions and classification for tumor diagnostics and treatment
InactiveUS20090082551A1Quick and easy determinationImprove survivalCompound screeningIn-vivo radioactive preparationsTumor BiomarkersSide effect
The present invention is directed towards classifying tumor biomarkers, particularly membrane receptors, and more particularly the gastrin-releasing peptide (GPR) receptors, identified in patient samples, then linking therapeutic agents (chemical, radiological, or biological) to patient-specific ligands that bind to such receptors, clinicians can produce diagnostic and treatment compositions and implement treatment regimens which, by using the classified and identified biomarkers, and due to their improved accuracy, increase success and decrease undesired side effects from such treatments.
Owner:ZUCKERMAN MATHEW MARK
Gastrin releasing peptide compounds
InactiveUS7922998B2Carbamic acid derivatives preparationOrganic compound preparationGastrin-releasing peptideImaging agent
Owner:BRACCO IMAGINIG SPA
Stabilizing alkylglycoside compositions and methods thereof
ActiveUS8173594B2Convenient treatmentReduce aggregationBiocidePeptide/protein ingredientsPeptide TGastrin-releasing peptide
The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or analog thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
Owner:AEGIS THERAPEUTICS LLC
Fusion protein capable of inducing and activating cancer targeting T-cells as well as preparation method and application of the fusion protein
ActiveCN102391377ACancer targetingGood killing effectBacteriaPeptide/protein ingredientsCancer targetingVascular endothelium
The invention discloses a fusion protein capable of inducing and activating cancer targeting T-cells as well as a preparation method and application of the fusion protein. The fusion protein contains peptide acting with cancer cells as well as costimulatory molecules B7.1, wherein the peptide acting with the cancer cells is selected from a transforming growth factor-alpha, an epidermal growth factor, a vascular endothelial growth factor, gonadotropinreleasing hormone or gastrin-releasing peptide. The fusion protein has a targeting function; the fusion protein can act with VEGFR, EGFR, GnRH-R, or GRP-R respectively on one hand and interact with corresponding receptors CD28 and CTLA-4 expressed on the T-cells, therefore the targeting of the T-cells is positioned at the periphery of the cancer cells greatly expressing VEGFR, EGFR, GnRH-R, or GRP-R. Proven by experiments, the fusion protein can restrain the growth of tumors and cause cancer cells to apoptosis.
Owner:孙嘉琳 +1
Chemiluminescence immune detection kit for detecting pro-gastrin-releasing peptide
InactiveCN105067599AThe electrophoretic method is fast and easyImprove throughputChemiluminescene/bioluminescenceGastrin-releasing peptideCarrier protein
The invention provides a chemiluminescence immune detection kit for detecting a pro-gastrin-releasing peptide; the chemiluminescence immune detection kit is composed of a non-transparent white elisa plate coated with the pro-gastrin-releasing peptide, a pro-gastrin-releasing peptide standard, a pro-gastrin-releasing peptide-peroxidase labelled antibody working liquid, a luminous substrate liquid, a concentrated sample diluent and a concentrated detergent. A pro-gastrin-releasing peptide protein conjugate is obtained by coupling the pro-gastrin-releasing peptide with a carrier protein by a mixed anhydride method or a carbodiimide method, and the concentrated detergent contains 0.05% of Twain-20. Compared with a conventional enzyme-linked immunosorbent assay, the kit has higher sensitivity, is short in detection time and low in cost, and can be used for detection of the pro-gastrin-releasing peptide in human blood or serum.
Owner:NANJING WENZHI BIOTECH
Gastrin Releasing Peptide Compounds
InactiveUS20070231257A1Peptide/protein ingredientsDigestive systemGastrin-releasing peptideImaging agent
Owner:BRACCO IMAGINIG SPA
Kit for predicating lung cancer risk for high-risk groups among China urban population on basis of CT (computed tomography) images and biomarker spectrums
ActiveCN105717146AEasy to measureMeasuring the expression levels of such biomarkers is simpleBiological testingMaterial analysis by transmitting radiationGastrin-releasing peptideSquamous Carcinomas
The invention discloses a kit for predicating lung cancer risk for high-risk groups among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The kit comprises a reagent for measuring the expression quantity of serum protein spectrums of the following four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens. The kit can be used for accurately predicating the lung cancer risk in combination of CT imageology parameters including nodule diameters, spicule signs and positions and other clinical indexes including age, the smoking history, the history of malignant tumor and genders.
Owner:上海超联智医学科技中心(有限合伙)
Non Peptide Agonists and Antagonists of Adrenomedullin and Gastric Releasing Peptide
This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (AM) or gastrin releasing peptide (GRP) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or blocking antibodies specific for the peptides, are also described, as are pharmaceutical compositions comprising the modulatory agents, and methods for using the modulatory agents to diagnose or treat patients.
Owner:US DEPT OF HEALTH & HUMAN SERVICES +1
Model for predicating lung cancer risks for people suffering from pulmonary nodules among China urban population on basis of CT (computed tomography) images and biomarker spectrums
ActiveCN105717147AEasy to measureMeasuring the expression levels of such biomarkers is simpleBiological testingMaterial analysis by transmitting radiationPulmonary nodulePositive control
The invention discloses a model for predicating lung cancer risks for people suffering from pulmonary nodules among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The model comprises biomarkers, enzyme-labeled antibodies of the biomarkers, a carbonate buffer solution with the pH value being 9.6, a phosphate buffer solution with a pH value being 7.4, a serum protein diluent, a stop solution, a tetramethyl benzidine substrate solution, serum of normal people and positive control serum; the biomarkers are four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens and are combined with CT imageology parameters and other clinical indexes. The model can assist in screening of lung cancer.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Gastrin Releasing Peptide Compounds
Owner:BRACCO IMAGINIG SPA
Targeted nanometer microbubble for treating small cell lung cancer as well as preparation method and application thereof
InactiveCN107661508AMolecular weight halvedDoes not affect antigen recognition efficiencyOrganic active ingredientsPharmaceutical delivery mechanismPreprogastrin-releasing peptideGastrin-releasing peptide
The invention provides a targeted nano-microbubble for treating small cell lung cancer, a preparation method and application thereof. Targeted nano-microbubbles include a lipid bimolecular shell and an inert gas wrapped inside the lipid bimolecular shell, and the anti-progastrin releasing peptide monoclonal antibody of small cell lung cancer and paclitaxel are connected to the lipid bimolecular shell, The average particle size of nano-microbubbles is 300-500nm. Preparation method: dipalmitolecithin, distearoylphosphatidylethanolamine, dipalmitophosphatidic acid and paclitaxel were completely dissolved in chloroform by film hydration method to prepare paclitaxel-containing liposomes, which are aimed at anti-progastrocytosis of small cell lung cancer The hormone-releasing peptide monoclonal antibody was opened with mercaptoethylamine, incubated with the liposome above to form a stable thioether bond, and then perfluoropropane gas was passed through, and the anti-monogastric antibody targeting small cell lung cancer was obtained by mechanical vibration. Secretin-releasing peptide monoclonal antibody targeting paclitaxel nanomicrobubbles. The targeted nanometer microbubble can be used in the preparation of medicines for treating small cell lung cancer.
Owner:SHANXI UNIV
Two-photon fluorescence immunochromatographic kit for quantitative determination of pro-gastrin-releasing peptide (pro-GRP) and preparation method thereof
InactiveCN107389928ALong fluorescence lifetimeHigh luminous intensityMaterial analysisSerum igePlasma samples
The invention discloses a two-photon fluorescence immunochromatographic kit using a fluorescent dye as a marker and used for quantitative determination of pro-GRP. The two-photon fluorescence immunochromatographic kit provided by the invention realizes fluorescent quantitative detection of pro-GRP, has the advantages of good stability, a wide linear range, good specificity, accurate quantification, easiness and quickness, can simultaneously detect whole blood, serum and plasma samples, and is applicable to all levels of hospitals and family practice.
Owner:重庆康巨全弘生物科技有限公司
New itch treatment using a combination of neurokinin-1, gastrin releasing peptide, and glutamate receptor antagonists
InactiveUS20150320827A1Avoid spreadingReduce excitementBiocidePeptide/protein ingredientsGastrin-releasing peptideNK1 receptor antagonist
Methods, and compositions are provided for inhibition of histamine and non-histamine dependent itch signal transmission or scratch behavior. In one aspect, the present invention further comprises administering to the subject an inhibitor of histamine-dependent itch signal transmission. In some cases, the inhibitor of histamine independent itch signal transmission comprises an NK-1 receptor antagonist or the inhibitor of histamine independent itch signal transmission comprises a GRP receptor antagonist. In some cases, the method comprises administering two inhibitors of histamine independent itch signal transmission. For example, the inhibitors of histamine independent itch signal transmission can comprise an NK-1 receptor antagonist and a GRP receptor antagonist. In another embodiment, the invention provides a method of treating itch comprising administering to a subject suffering from itch an NK-1 receptor antagonist, a GRP receptor antagonist.
Owner:RGT UNIV OF CALIFORNIA
Gastrin releasing peptide compounds
InactiveUS20060239914A1Improve targetingUltrasonic/sonic/infrasonic diagnosticsPeptide/protein ingredientsGastrin-releasing peptideImaging agent
New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and / or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.
Owner:BRACCO IMAGINIG SPA
Methods of treating lung disease and other inflammatory diseases
InactiveUS20130280270A1BiocideOrganic active ingredientsGastrin-releasing peptideInflammatory disorder
A method of treating an inflammatory disease in a subject in need thereof is carried out by administering the subject a gastrin-releasing peptide (GRP) inhibitor in a treatment effective amount. Suitable GRP inhibitors include compounds of the general formula:and pharmaceutically acceptable salt or prodrugs thereof.
Owner:SUNDAY MARY E +3
Gastrin releasing peptide compounds
Owner:BRACCO IMAGINIG SPA
Antibody directed against pro-gastrin releasing peptide, and use thereof
ActiveUS20100248274A1The result is stableReduce the amount requiredDisease diagnosisTissue cultureEpitopeGastrin-releasing peptide
Disclosed is a novel high-sensitive ProGRP measurement method, which is free from problems such as the fluctuations in measurement values and the operational constraints (e.g., the constraints on the handling of a sample). Specifically disclosed is a method for the measurement of a gastrin-releasing peptide precursor and / or a digested product thereof using at least two different antibodies each of which can recognize an epitope represented by the amino acid sequence consisting of amino acid 47 to amino acid 68 of the amino acid sequence set forth in SEQ ID NO:1. The method can detect a ProGRP or a digested product thereof in a refrigerated sample within a shorter period, by using the sample in a smaller amount, and with a higher degree of detective sensitivity, compared with the conventional methods.
Owner:ADVANCED LIFE SCI INST
Improved gastrin releasing peptide compounds
InactiveCN1897980AStable formationLess reservedIn-vivo radioactive preparationsRadiation therapyGastrin-releasing peptideImaging agent
New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N-O-P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and / or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.
Owner:BRACCO IMAGINIG SPA
Gastrin-releasing peptide (GRP) guided fusion protein
InactiveCN102250252APharmaceutical non-active ingredientsAntibody medical ingredientsGastrin-releasing peptideToxin
The invention relates to a fusion protein which can directionally kill tumor cells. The fusion protein comprises a guiding part composed of gastrin-releasing peptide (GRP) and an effect part composed of cytotoxin, and has a characteristic of directionally reaching and killing tumor cells which overexpress GRP receptors.
Owner:MILITARY VETERINARY RES INST PLA MILITARY MEDICAL ACAD OF SCI
Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
InactiveUS7795385B2Lessen lung damageImprove survivalAntibacterial agentsNervous disorderModerate depressionGastrin-releasing peptide
The invention concerns the use of a bombesin / gastrin releasing peptide antagonist in the treatment of inflammatory and immune-mediated inflammatory conditions, in particular sepsis, acute lung injury and rheumatoid arthritis as well as for the treatment or prophylaxis of brain disorders, preferably bipolar disorder, and in particular the different forms and / or subforms of bipolar disorder, such as mania, acute mania, severe mania, hypomania, depression, moderate depression, dysthymia, severe depression, episodes of mania and / or depression, psychosis / psychotic symptoms (e.g. hallucinations, delusions), mixed bipolar state, bipolar I disorder, bipolar II disorder and / or rapid-cycling bipolar disorder. In particular, specific nonapeptides with antagonist properties against bombesin or bombesin-like peptides, such as the gastrin releasing peptide, may be used in the treatment of inflammatory and immune-mediated inflammatory conditions as well as brain disorders.
Owner:CRISTALIA PROD QUI FARM LTDA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com